JiXing is a leading biotechnology company committed to bringing innovative science and medicines to underserved patients in China.
We formed JiXing in early 2020, borne out of a two-year study of innovation, biotechnology, and access to healthcare in China. JIXING is a leading biotechnology company headquartered in Shanghai committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
Backed by RTW, JiXing partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, industry leading talent, and patient-centric focus, JiXing is dedicated to delivering a meaningful and lasting impact on patients in Greater China.
JiXing’s pipeline now includes 7 assets focused on cardiovascular and ophthalmology conditions with high unmet need through partnerships with Cytokinetics, Milestone, LENZ Therapeutics, and Oyster Pharma. RTW further capitalized JiXing by providing a Series B and C funding.